Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Rating) have earned an average recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating […]
Travere Therapeutics (NASDAQ:TVTX – Get Rating) had its price objective increased by Guggenheim from $37.00 to $40.00 in a research note released on Monday, The Fly reports. Several other research firms have also issued reports on TVTX. Stifel Nicolaus started coverage on shares of Travere Therapeutics in a research note on Tuesday, December 13th. They […]